BioCentury
ARTICLE | Company News

CHMP recommendations include Keytruda for NSCLC

June 25, 2016 12:22 AM UTC

EMA's CHMP recommended approval of PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) for non-small cell lung cancer, as well as asthma treatment Cinqaero reslizumab from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and cell therapy Zalmoxis from MolMed S.p.A. (Milan:MLM).

The committee recommended Keytruda's approval to treat locally advanced or metastatic NSCLC in adults whose tumors express PD-L1 and who have received at least one prior therapy. The drug is already approved in the EU and U.S. for advanced melanoma, and in the U.S. for NSCLC that expresses PD-L1 and that has progressed on or after platinum-based chemotherapy. ...